Differences in small airways disease between asymptomatic and symptomatic subjects with airway hyperresponsiveness

Differences in small airways disease between asymptomatic and symptomatic subjects with airway hyperresponsiveness - AHR and small airways

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37837

Enrollment

Registered

2012-05-16

Start date

2012-05-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma oversensitive airways

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for asymptomatic subjects without AHR : • Age between 18 and 65 years. • FEV1 > 80% predicted post bronchodilator. • PC20 methacholine 80% predicted post bronchodilator. • PC20 methacholine >8 mg/ml. • No history of asthma or previous use of asthma medication.;Inclusion criteria for patients with asthma: • Age between 18 and 65 years. • FEV1 > 80% predicted. • PC20 methacholine

Exclusion criteria

Exclusion criteria: • Use of inhaled or oral steroids, antihistamines, nedocromil, theophylline, leukotrien antagonists or long-acting beta-agonists for at least three weeks before the start of the study. • Any disease that may affect the outcome of the study as judged by the Investigator. • FEV1

Design outcomes

Primary

Measure	Time frame
peripheral airway resistance, measured with IOS	—

Secondary

Measure	Time frame
Peripheral airway resistance measured with IOS during provocationtest Other small airways parameters: - FEF25-75 - alveolar NO - RV, RV/TLC mRNA expression in nasal epithelium.	—

Countries

Netherlands

Outcome results